The use of HLA-A*0201-transfected K562 as standard antigen-presenting cells for CD8(+) T lymphocytes in IFN-gamma ELISPOT assays - PubMed (original) (raw)
The use of HLA-A*0201-transfected K562 as standard antigen-presenting cells for CD8(+) T lymphocytes in IFN-gamma ELISPOT assays
Cedrik M Britten et al. J Immunol Methods. 2002.
Abstract
ELISPOT assays are increasingly used for a direct detection and quantification of single antigen-specific T cells in freshly isolated peripheral blood mononuclear cells (PBMC). They are particularly attractive for the monitoring of specific T lymphocyte responses in clinical trials assessing antigen-specific immunizations in patients with cancer or chronic viral infections. However, one major limitation for the broad clinical implementation of ELISPOT assays is the lack of an inexhaustible source of suitable HLA-matched antigen-presenting cells (APC). Currently available allogeneic or xenogeneic APC (such as the human lymphoid hybrid T2 or HLA-transfected insect cells) can either lead to strong background spot production by APC-reactive T lymphocytes or have a low antigen presentation capability. Both phenomena can prevent the detection of low frequency T cell responses in PBMC. In search of alternative APC for ELISPOT assays, the human chronic myelogenous leukemia cell line K562 that per se does not express HLA class I and class II molecules on the cell surface was transfected with the HLA-A*0201 gene. Clonal HLA-A*0201-expressing K562 (K562/A*0201) cells were able to process and present endogenously expressed and exogenously loaded melanoma peptide antigens to HLA-A*0201-restricted cytolytic T lymphocyte clones in cytotoxicity and IFN-gamma ELISPOT assays. K562/A*0201 cells were then used as APC in IFN-gamma spot assays to detect ex vivo CD8(+) T lymphocytes responsive to known HLA-A*0201-binding peptide epitopes derived from cytomegalovirus, Epstein-Barr virus, influenza virus and melanoma in PBMC from HLA-A*0201-positive donors. In the majority of cases, peptide-pulsed K562/A*0201 cells were similarly efficient in the ability to visualize single antigen-specific CD8(+) T lymphocytes when compared to T2 cells. However, in contrast to T2, background reactivity of CD8(+) T cells responsive to unpulsed K562/A*0201 was regularly found to be negligible, thereby enhancing the sensitivity of the ELISPOT assay, particularly in donors with strong anti-T2 reactivity. K562 cells transfected with HLA-A*0201 or other HLA genes can serve as standard APC for monitoring T lymphocyte responses against tumor and viral peptide antigens.
Similar articles
- Insect cells as HLA-restricted antigen-presenting cells for the IFN-gamma elispot assay.
Janetzki S, Song P, Gupta V, Lewis JJ, Houghton AN. Janetzki S, et al. J Immunol Methods. 2000 Feb 3;234(1-2):1-12. doi: 10.1016/s0022-1759(99)00203-3. J Immunol Methods. 2000. PMID: 10669764 - The use of clonal mRNA as an antigenic format for the detection of antigen-specific T lymphocytes in IFN-gamma ELISPOT assays.
Britten CM, Meyer RG, Frankenberg N, Huber C, Wölfel T. Britten CM, et al. J Immunol Methods. 2004 Apr;287(1-2):125-36. doi: 10.1016/j.jim.2004.01.026. J Immunol Methods. 2004. PMID: 15099761 - In vitro expansion of Ag-specific T cells by HLA-A*0201-transfected K562 cells for immune monitoring.
Yuan J, Gallardo HF, Rasalan T, Ranganathan R, Wang J, Zhang Y, Panageas K, Stan R, Young JW, Houghton AN, Wolchok JD. Yuan J, et al. Cytotherapy. 2006;8(5):498-508. doi: 10.1080/14653240600868262. Cytotherapy. 2006. PMID: 17050255 Clinical Trial. - Quantification of tumor-specific T lymphocytes with the ELISPOT assay.
Schmittel A, Keilholz U, Thiel E, Scheibenbogen C. Schmittel A, et al. J Immunother. 2000 May-Jun;23(3):289-95. doi: 10.1097/00002371-200005000-00001. J Immunother. 2000. PMID: 10838657 Review. - Antigen presenting cells integrate opposing signals from CD4+ and CD8+ regulatory T lymphocytes to arbitrate the outcomes of immune responses.
Lederman S, Suciu-Foca N. Lederman S, et al. Hum Immunol. 1999 Jul;60(7):533-61. doi: 10.1016/s0198-8859(99)00045-2. Hum Immunol. 1999. PMID: 10426271 Review.
Cited by
- Infusion Product TNFα, Th2, and STAT3 Activities Are Associated with Clinical Responses to Transgenic T-cell Receptor Cell Therapy.
Nowicki TS, Peters CW, Quiros C, Kidd CK, Kawakami M, Klomhaus AM, Baselga-Carretero I, Kaplan-Lefko P, Macabali MH, Perez Garcilazo I, Berent-Maoz B, Comin-Anduix B, Ribas A. Nowicki TS, et al. Cancer Immunol Res. 2023 Dec 1;11(12):1589-1597. doi: 10.1158/2326-6066.CIR-23-0577. Cancer Immunol Res. 2023. PMID: 37871333 Free PMC article. - Physical and in silico immunopeptidomic profiling of a cancer antigen prostatic acid phosphatase reveals targets enabling TCR isolation.
Mao Z, Nesterenko PA, McLaughlin J, Deng W, Burton Sojo G, Cheng D, Noguchi M, Chour W, DeLucia DC, Finton KA, Qin Y, Obusan MB, Tran W, Wang L, Bangayan NJ, Ta L, Chen CC, Seet CS, Crooks GM, Phillips JW, Heath JR, Strong RK, Lee JK, Wohlschlegel JA, Witte ON. Mao Z, et al. Proc Natl Acad Sci U S A. 2022 Aug 2;119(31):e2203410119. doi: 10.1073/pnas.2203410119. Epub 2022 Jul 25. Proc Natl Acad Sci U S A. 2022. PMID: 35878026 Free PMC article. - Insights Into the Emergence of Paroxysmal Nocturnal Hemoglobinuria.
Colden MA, Kumar S, Munkhbileg B, Babushok DV. Colden MA, et al. Front Immunol. 2022 Jan 28;12:830172. doi: 10.3389/fimmu.2021.830172. eCollection 2021. Front Immunol. 2022. PMID: 35154088 Free PMC article. Review. - HLA-DPB1 Reactive T Cell Receptors for Adoptive Immunotherapy in Allogeneic Stem Cell Transplantation.
Klobuch S, Hammon K, Vatter-Leising S, Neidlinger E, Zwerger M, Wandel A, Neuber LM, Heilmeier B, Fichtner R, Mirbeth C, Herr W, Thomas S. Klobuch S, et al. Cells. 2020 May 20;9(5):1264. doi: 10.3390/cells9051264. Cells. 2020. PMID: 32443793 Free PMC article. - Rapid Assessment of Functional Avidity of Tumor-Specific T Cell Receptors Using an Antigen-Presenting Tumor Cell Line Electroporated with Full-Length Tumor Antigen mRNA.
Campillo-Davo D, Versteven M, Roex G, Reu H, Heijden SV, Anguille S, Berneman ZN, Tendeloo VFIV, Lion E. Campillo-Davo D, et al. Cancers (Basel). 2020 Jan 21;12(2):256. doi: 10.3390/cancers12020256. Cancers (Basel). 2020. PMID: 31972992 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials